Salix Pharmaceuticals, Inc v. Mylan Pharmaceuticals, Inc.
1:15-cv-00109
Overview
Parties
Plaintiff
Counter Claimant
Counter Defendant
Court & Judges
Court
District Court, N.D. West Virginia (wvnd)
Presiding Judge
Global Patent Family Cross-Litigation Radar
CasLoc 360° Radar 3 Family MembersMulti-jurisdiction dispute tracking across USPTO PTAB, U.S. Federal Courts, Unified Patent Court (UPC), and EPO Oppositions
| Jurisdiction | Publication Number | Relationship | Official Record |
|---|---|---|---|
| 🇺🇸 United States | Asserted | US Continuation / Sibling | View Official Patent → |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → | |
| 🇺🇸 United States | US Continuation / Sibling | View Official Patent → |
MycoNovo, Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.
Mylan Pharmaceuticals Inc. et al. v. Salix Pharmaceuticals, Ltd. et al.
GeneriCo, LLC et al. v. SALIX PHARMACEUTICALS, LTD. et al.
Salix Pharmaceuticals, Inc. v. Teva Pharmaceuticals USA, Inc.
Salix Pharmaceuticals Inc. v. Novel Laboratories Inc.
Salix Pharmaceuticals Inc. v. G & W Laboratories, Inc.
Patents Involved
There is a single patent involved in this case.
| Patent Asset | Filing & Issue Date | Expiration & Term Status | External Links |
|---|---|---|---|
|
US8865688
Compositions and methods for treatment of bowel diseases with granulated mesalamine
|
Filed: 2009-10-02
Issued: 2014-10-21
|
Active (3.4 yrs remaining)
+211d PTA
Expires: 2030-05-01
|
Patent Enforceability & Injunction Risk Assessment
Active Threat — Patent is within enforceable statutory term; injunctive relief viable.
High PTA (+211 days) / In re Cellect scrutiny applies.
Under 35 U.S.C. § 286, damages cannot accrue for infringement prior to 6 years before filing. All Statutory Maintenance Fees Paid (12-Year Window Cleared).
Procedural Motions & Interlocutory Orders
Total Motions
61
Dispositive
0
Granted
25
Denied
0
Pending / Review
33
Motions by Category
Key Dispositive Motions & Rulings